Send to

Choose Destination
Endocrinol Nutr. 2016 Nov;63(9):466-474. doi: 10.1016/j.endonu.2016.05.011. Epub 2016 Aug 30.

Clinical and economic benefits of integrated pump/CGM technology therapy in patients with type 1 diabetes in Colombia.

[Article in English, Spanish]

Author information

Hospital Universitario de San Ignacio-Universidad Javeriana, Bogotá, Colombia. Electronic address:
University of Washington, Seattle, WA, EE. UU.; RANDOM Foundation, Bogotá, Colombia.
Medtronic PLC Andean Region, Bogotá, Colombia.
Medtronic Diabetes Inc., Northridge, CA, EE. UU.
University of Washington, Seattle, WA, EE. UU.
Ossian Health Economics and Communications, Basilea, Suiza.
HEVA HEOR, Lyon, Francia.
Medtronic Latinamerica Inc., Miami, FL, EE. UU.



To assess the long-term clinical and economic impact of integrated pump/CGM technology therapy as compared to multiple daily injections (MDI), for the treatment of type 1 diabetes (T1D) in Colombia.


The CORE Diabetes Model was used to simulate a hypothetical cohort of patients with T1D. Mean baseline characteristics were taken from a clinical study conducted in Colombia and a healthcare payer perspective was adopted, with a 5% annual discount rate applied to both costs and outcomes.


The integrated pump/CGM improved mean life expectancy by 3.51 years compared with MDI. A similar increase occurred in mean quality-adjusted life expectancy with an additional 3.81 quality-adjusted life years (QALYs). Onset of diabetes-related complications was also delayed as compared to MDI, and mean survival time free of complication increased by 1.74 years with integrated pump/CGM. Although this increased treatment costs of diabetes as compared to MDI, savings were achieved thanks to reduced expenditure on diabetes-related complications. The estimated incremental cost-effectiveness ratio (ICER) for SAP was Colombian Pesos (COP) 44,893,950 (approximately USD$23,200) per QALY gained.


Improved blood glucose control associated to integrated pump/CGM results in a decreased incidence of diabetes-related complications and improves life expectancy as compared to MDI. Using recommended thresholds from the World Health Organization and previous coverage decisions about health technologies in Colombia, it is a cost-effective alternative to MDI for the treatment of type 1 diabetes in Colombia.


Análisis de coste-efectividad; Continuous glucose monitoring; Cost-effectiveness analysis; Decision modeling; Diabetes tipo 1; Insulin infusion systems; Modelamiento de decisiones.; Monitorización continua de glucosa; Sistemas de infusión de insulina; Type 1 diabetes

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Ediciones Doyma, S.L.
Loading ...
Support Center